弥漫性半球胶质瘤H3 G34突变型:通过单机构病例系列和文献分析明确其临床特征
本研究结合单机构6例病例系列与截至2025年1月的文献综述,共分析514例弥漫性半球胶质瘤H3 G34突变型患者(其中257例有个体水平生存数据)。中位年龄16岁,中位总生存期21个月;全切较次全切和活检显著改善生存,右半球原发肿瘤生存更长,H3 p.G35V较p.G35R突变生存更短,年龄、MGMT启动子甲基化、TP53/ATRX/PDGFRA突变及强化对生存无显著影响。
要点
- 全切较次全切和活检显著改善总生存(Log-rank p < 0.001)。
- H3 p.G35V较p.G35R突变患者总生存更短(Log-rank p = 0.01)。
- 年龄、MGMT启动子甲基化、TP53/ATRX/PDGFRA突变及强化与生存无显著差异。
核心结论
- 本研究呈现迄今最大的DHG, H3 G34合并数据集,更清晰描述影响该病生存的预后因素。
- 与许多原发性脑肿瘤包括胶质母细胞瘤及青少年和年轻成人肿瘤不同,生存似乎不受年龄显著影响。
研究设计与样本
- 单机构病例系列(n = 6)并结合截至2025年1月的既往个体病例文献综述。
- 共识别514例DHG, H3 G34病例用于分析,其中257例有个体水平生存数据。
- 采用Kaplan-Meier法进行生存分析,并采用Cox回归。
主要发现
- 队列中位年龄16岁(范围:1-66岁),中位总生存期21个月。
- 全切较次全切和仅活检改善总生存(Log-rank p < 0.001)。
- 原发肿瘤位于右半球者较其他部位总生存更长(Log-rank p < 0.001)。
- H3 p.G35V(G34V)突变较p.G35R突变总生存更短(Log-rank p = 0.01)。
- 按患者年龄、MGMT启动子甲基化状态、TP53/ATRX/PDGFRA突变存在与否或对比强化,生存结局无差异。
关键数值与推荐
- 全切较次全切和仅活检改善总生存(Log-rank p < 0.001)。
- 右半球原发肿瘤较其他部位总生存更长(Log-rank p < 0.001)。
- H3 p.G35V较p.G35R突变总生存更短(Log-rank p = 0.01)。
- 年龄、MGMT启动子甲基化、TP53/ATRX/PDGFRA突变及对比强化与生存无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diffuse hemispheric glioma, H3 G34-mutant (DHG, H3 G34) is an uncommon new tumor type defined in the World Health Organization 2021 classification. DHG, H3 G34 primarily affects children and young adults. There is paucity of knowledge regarding its demographic and prognostic factors. We present an institutional case series and a comprehensive literature review to better determine factors contributing to overall survival. METHODS: We included an institutional case series (n = 6) and comprehensively reviewed previously published individual cases of DHG, H3 G34 through January 2025. A total of 514 individual cases of DHG, H3 G34 were identified and utilized for analyses (n = 257 with individual level survival data). We performed survival analysis using the Kaplan-Meier method and Cox regression. RESULTS: Median age of the cohort was 16 years (range: 1-66 years). Median OS was 21 months. OS was improved with gross total resection compared to subtotal resection and biopsy only (Log-rank p < 0.001). Patients with primary tumor location in the right hemisphere had longer OS relative to other tumor locations (Log-rank p < 0.001). Patients with H3 p.G35V (G34V) mutations as opposed to p.G35R mutations had shorter OS (Log-rank p = 0.01). There was no difference in survival outcomes by patient age, MGMT promoter methylation status, the presence of TP53/ATRX/PDGFRA mutations or contrast enhancement. CONCLUSIONS: We present the largest combined data set of patients with DHG, H3 G34 to date and describe in greater clarity the prognostic factors which impact survival in this disease. Unlike many primary brain tumors including glioblastoma and tumors in adolescents and young adults, survival does not appear to be significantly impacted by age.
引用
- Williams A, Neth B, Webb M, et al. Diffuse hemispheric glioma, H3 G34-mutant: defining the clinical picture through a single institution case series and literature analysis. J Neurooncol. 2025. PMID: 40402198. doi:10.1007/s11060-025-05028-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。